Benjamin Katchman

Benjamin Katchman, PhD has worked in a variety of positions in the research and development field since 2002. Benjamin began their career as an Undergraduate Research Assistant in Dr. Milton Taylor's Laboratory at Indiana University Bloomington, where they validated and evaluated microarray results from patients in clinical trials for Interferon treatment for Hepatitis C. Benjamin then moved to Cleveland Clinic, where they were an Undergraduate Research Assistant in Dr. Bryan R. G. Williams' Laboratory. In 2005, they became a Research Associate in Dr. Sunil Chatterjee's Laboratory at The Vontz Molecular Studies Center at Cincinnati University, Cincinnati, Ohio, where they utilized in vitro and in vivo models to evaluate a vaccinia virus based therapeutic vaccine targeting TGF-beta for the treatment of head and neck squamous cell carcinoma.

In 2008, Benjamin began their PhD in Molecular and Cellular Biology at Arizona State University's School of Life Sciences, where they utilized multiple proteomic and biochemical approaches to identify novel serum and tissue tumor biomarkers. Benjamin also became a Postdoctoral Research Associate in Dr. Karen S. Anderson and Joshua LaBaer's lab at Arizona State University's Biodesign Institute, Center for Personalized Diagnostics.

In 2016, Benjamin co-founded FlexBioTech Inc. to develop novel protein, antibody, and nucleic acid micorarray based handheld and wearable point-of-care diagnostics. Benjamin also became a Principal Scientist at Eccrine Systems, Inc., where they were the Principal Investigator on sweat biomarker discovery and validation, using advanced proteomic, genomic and metabolomic techniques. Benjamin also designed novel customizable and multiplexed aptamer-based arrays of fluorescent and electrochemical biosensors for rapid and continuous detection of biomarkers in sweat.

In 2018, Benjamin became Vice President of Research and Development at PathogenDx, where they worked with the COO to restructure the entire R&D and manufacturing organization to streamline product development, validations, and quality control through the introduction of design control from product conception through transfer to manufacturing achieving ISO9001 (in process ISO13485). Benjamin owned the development and commercialization timeline for all of PathogenDx's healthcare and food safety products, and expanded the company into the healthcare field developing, validating and receiving FDA-EUA status for a novel DNA microarray that detects SARS-CoV-2 and Influenza A/B (DetectX-Rv). Benjamin also led a team of 4 scientists in the development and validation of a series of novel DNA microarrays for the detection and quantification of bacterial and fungal pathogens found in food, agriculture, environmental and cannabis products, and managed day to day interactions with current and future customers.

Currently, Benjamin is the Director of Research and Development at LungLife AI.

Benjamin Katchman, PhD obtained their PhD in Molecular and Cellular Biology from Arizona State University between 2007 and 2012. Prior to that, they obtained a B/S in Microbiology from Indiana University Bloomington between 2001 and 2005.